Treatment of orbital metastases from a primary midgut neuroendocrine tumor with peptide-receptor radiolabeled therapy using 177 lutetium-DOTATATE

J Clin Oncol. 2013 Jun 10;31(17):e272-5. doi: 10.1200/JCO.2012.45.8612. Epub 2013 Apr 29.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Humans
  • Lutetium / administration & dosage*
  • Male
  • Neuroendocrine Tumors / pathology
  • Neuroendocrine Tumors / radiotherapy*
  • Octreotide / administration & dosage
  • Octreotide / analogs & derivatives*
  • Orbital Neoplasms / radiotherapy*
  • Orbital Neoplasms / secondary*
  • Organometallic Compounds / administration & dosage*
  • Radioisotopes / administration & dosage*
  • Radiopharmaceuticals / administration & dosage*

Substances

  • Organometallic Compounds
  • Radioisotopes
  • Radiopharmaceuticals
  • Lutetium
  • lutetium Lu 177 dotatate
  • Octreotide